Navigation Links
Sequenom Announces Paul Maier to Become Interim Chief Financial Officer
Date:10/26/2009

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced that Paul V. Maier has been appointed as the company's interim chief financial officer effective November 10, 2009, reporting directly to the company's interim chief executive officer and chairman of the board, Harry F. Hixson, Jr., Ph.D.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

Prior to the effective date of Mr. Maier's appointment as interim chief financial officer, Mr. Maier will act as a consultant to the company.

"I am delighted that Paul has agreed to join Sequenom as our interim CFO," said Dr. Hixson. "His wealth of experience, including over 20 years in the pharmaceutical and biotechnology industry makes him an ideal fit for us. Paul will play an important role as we look to strengthen our financial position and strategically position ourselves for product launches and growth."

Mr. Maier has been an independent financial consultant since February 2007. Mr. Maier served as senior vice president and chief financial officer of Ligand Pharmaceuticals Incorporated from 1992 until January 2007, where he helped build Ligand from a venture stage boutique company to a commercial, integrated biopharmaceutical organization. During his tenure at Ligand, Mr. Maier helped raise over $1 billion in equity and debt financings. Prior to Ligand, Mr. Maier spent six years in various management and finance positions at ICN Pharmaceuticals.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM® is a registered trademark of Sequenom, Inc.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's anticipated retention as a consultant and subsequent employment of Mr. Maier and the Company's financial position and positioning for product launches and growth, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's ability to retain and employ Mr. Maier, the Company's ability to strengthen its financial position, position itself for product launches and growth and develop and commercialize new technologies and products, particularly new technologies such as genetic analysis platforms, noninvasive prenatal diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

SOURCE Sequenom, Inc.


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... A recent research report published by Grand ... is expected to reach a value of $55.8 billion by 2025. ... 28 states have legalized marijuana for medical uses. In 2016, states ... , North Dakota , Ohio ... the drug in medical applications such as chemotherapies and pain management. ...
(Date:2/27/2017)... 27, 2017 Period October – December 2016 ... result amounted to SEK -16.4 (-6.4) million Result after tax ... before and after dilution Cash flow from operating activities amounted ... ... (0.4) million Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Wireless Health Market is ... next decade to reach approximately $330.5 billion by 2025. ... the given segments on global as well as regional levels presented ...
Breaking Medicine Technology:
(Date:2/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... use disorder, but concern for women who become dependent on opioid painkillers has fallen ... among female patients, compared to a 237% increase in fatal overdoses in male populations.(1) ...
(Date:2/27/2017)... ... ... Orange County dentist, Dr. A. Rassouli, comments on the new ... bacteria in plaque infect the gums and other tissues supporting the teeth. Treatment typically ... SRP, and can include surgical therapies if the condition has led to significant damage. ...
(Date:2/27/2017)... ... ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and Associated ... Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss any ... into a single volume a compelling argument that the disease does exist in his ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... center for hair transplantation therapy, is proud to announce a new informational post ... hair therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of ... concern over nerve agents and the deadly use of chemical weapons. Many questions exist ... how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan ...
Breaking Medicine News(10 mins):